CD274 and neoplasm: Studies have reported ORR of <5% in unselected patients (5), attributed to the disease’s immune-evasive features, including low tumor mutational burden (TMB), immune cell exclusion, and upregulation of immune-suppressive pathways such as PD-L1 (6).These challenges underscore the urgent need for novel therapeutic approaches that can overcome the immunosuppressive microenvironment and target specific tumor antigens.